[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100437020":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":35,"centralContacts":39,"locations":46,"responsibleParty":64,"collaborators":66,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":51,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":49,"whyStopped":51,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Low titer with two doses of HB Vaccines","EXPERIMENTAL","anti-HBs titer 2.5-10 mIU\u002FmL with two doses of HB Vaccines at Day 0 and Day 28",[13],"Biological: recombinant hepatitis B vaccine",{"label":15,"type":16,"description":17,"interventionNames":18},"Low titer with one dose of HB Vaccine","ACTIVE_COMPARATOR","anti-HBs titer 2.5-10 mIU\u002FmL with one dose of HB Vaccine at Day 0",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Extremely low titer with two doses of HB Vaccines","anti-HBs titer lower than 2.5 mIU\u002FmL with two doses of HB Vaccines at Day 0 and Day 28",[13],{"label":24,"type":16,"description":25,"interventionNames":26},"Extremely low titer with one dose of HB Vaccine","anti-HBs titer lower than 2.5 mIU\u002FmL with one dose of HB Vaccine at Day 0",[13],[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"BIOLOGICAL","recombinant hepatitis B vaccine","Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.",[24,20,15,9],[34],"Engerix-B",[36],{"name":37,"affiliation":5,"role":38},"CHYI-FENG JAN, MD, PhD","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"CHYI-FENG JAN, MD, PHD","CONTACT","+886-2-23123456","66824","jcf036@gmail.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Family Medicine, NTUH","RECRUITING","Taipei",null,"100","Taiwan","TW",{"type":56,"coordinates":57},"Point",[58,59],121.52639,25.05306,{"lat":59,"lon":58},[62],{"name":37,"role":42,"phone":43,"phoneExt":44,"email":63},"jcf036@ntuh.gov.tw",{"type":65,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[67,69],{"name":68,"class":6},"Academia Sinica, Taiwan",{"name":70,"class":71},"Ministry of Science and Technology, Taiwan","OTHER_GOV","100437020","the-immune-responses-after-hepatitis-b-revaccination-doses-in-a-young-cohort-100437020",false,"NCT04970836","The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","IRHBRVD","Inclusion Criteria:\n\n1. The actual age at the time of admission was higher than 20 years old and birth year after 1987\n2. Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.\n3. Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline\n4. Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire\n5. Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process\n6. In good health\n\nExclusion Criteria:\n\n1. Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)\n2. Those who have been vaccinated against hepatitis B during childhood and adolescence\n3. Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen",true,"ALL","20 Years","36 Years",{"count":84,"type":85},240,"ESTIMATED","INTERVENTIONAL",[88],"NA","This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\\\u003C10 mIU\u002FmL) need to take.",[91,92,93],"Hepatitis B","Vaccination; Infection","Preventable Disease, Vaccine",[95,96,97,98],"hepatitis B vaccine","revaccination","young adult","booster","2025-03-17",{"date":101,"type":102},"2025-03-20","ACTUAL",{"date":104,"type":102},"2021-08-01",{"date":106,"type":85},"2027-12-31",{"name":5,"class":6},1]